nbi 27914 has been researched along with nbi-34041 in 1 studies
| Studies (nbi 27914) | Trials (nbi 27914) | Recent Studies (post-2010) (nbi 27914) | Studies (nbi-34041) | Trials (nbi-34041) | Recent Studies (post-2010) (nbi-34041) |
|---|---|---|---|---|---|
| 76 | 0 | 29 | 5 | 1 | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodbeck, R; De Lombaert, S; Doller, D; Fung, L; Ge, P; Gulianello, M; Hodgetts, KJ; Hoffman, D; Horvath, RF; Kehne, JH; Kieltyka, A; Krause, JE; Lee, Y; Maynard, GD; Yoon, T | 1 |
1 other study(ies) available for nbi 27914 and nbi-34041
| Article | Year |
|---|---|
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
Topics: Adipose Tissue; Administration, Oral; Adrenocorticotropic Hormone; Animals; Biological Availability; Blood-Brain Barrier; Cell Line; Cerebral Cortex; Humans; In Vitro Techniques; Injections, Intraventricular; Male; Microsomes, Liver; Motor Activity; Pyrazines; Radioligand Assay; Rats; Receptors, Corticotropin-Releasing Hormone; Restraint, Physical; Structure-Activity Relationship | 2011 |